Nashville, TN, United States of America

Irene Zagol-Ikapitte

This inventor holds 3 USPTO granted patents. Top assignee: Vanderbilt University. Active years: 2019-2022.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2019-2022

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Irene Zagol-Ikapitte

Introduction

Irene Zagol-Ikapitte is a prominent inventor based in Nashville, TN (US). She has made significant contributions to the field of medical science, particularly in the area of platelet activation. With a total of 3 patents to her name, her work has the potential to impact patient care and treatment options.

Latest Patents

Irene's latest patents focus on methods of preventing platelet activation. One of her notable inventions is a method aimed at reducing the occurrence of malondialdehyde and/or levuglandin protein modification in a subject. This method involves administering an effective amount of at least one reactive dicarbonyl scavenger compound, or a pharmaceutically acceptable salt thereof. Another patent also addresses the same issue but utilizes a different approach with a γ-KA scavenger compound.

Career Highlights

Irene Zagol-Ikapitte is affiliated with Vanderbilt University, where she conducts her research and develops her innovative solutions. Her work is recognized for its potential to advance medical treatments and improve patient outcomes.

Collaborations

Irene collaborates with esteemed colleagues such as John A. Oates and Olivier Boutaud. These partnerships enhance her research and contribute to the development of her patented methods.

Conclusion

Irene Zagol-Ikapitte's contributions to the field of medical science through her innovative patents demonstrate her commitment to improving healthcare. Her work continues to pave the way for advancements in the prevention of platelet activation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…